# X4 Pharmaceuticals (XFOR) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/XFOR
## Company Profile
- Ticker: XFOR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 4.29 USD
- Market cap: 381051571.84 USD
- Last updated: 2026-08-12
## Business Overview
### Rare Hematology Focus
X4 Pharmaceuticals develops therapies for rare disorders in which dysregulated CXCR4 signaling contributes to abnormal retention of immune cells in bone marrow. Its lead molecule, mavorixafor, is an oral CXCR4 antagonist designed to mobilize neutrophils into circulation.
### Chronic Neutropenia Development
Mavorixafor is being evaluated in the global pivotal 4WARD Phase 3 trial for congenital, acquired primary autoimmune and idiopathic chronic neutropenia. The study tests once-daily mavorixafor, with or without G-CSF, in patients who experience recurrent or serious infections.
### Approved WHIM Syndrome Product
Mavorixafor is approved as XOLREMDI for WHIM syndrome, including authorization in the European Union. X4 has partnered with Norgine for European commercialization, giving the company a partner-led route to expand access while concentrating internal resources on clinical development.
## Why The Stock Is Moving

As of Aug 12, 2026, XFOR was little changed and closed at $4.29. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of enrollment in the 4WARD Phase 3 chronic neutropenia trial expected by the end of the third quarter of 2026.
- Transfer of the European XOLREMDI marketing authorization to Norgine planned later in 2026.

## Recent News
- 2026-08-06 20:15 EST — [X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-co-879da21b) — Source: X4 Pharmaceuticals
- 2026-07-07 20:30 EST — [X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--477fc08a) — Source: X4 Pharmaceuticals
- 2026-07-01 11:00 EST — [X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-appoints-kelly-gold-experienced-chief-financial-officer-to-it-316d9f27) — Source: X4 Pharmaceuticals
- 2026-05-27 11:00 EST — [X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-7aa62ad2) — Source: X4 Pharmaceuticals
- 2026-05-06 11:15 EST — [X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-cor-86158817) — Source: X4 Pharmaceuticals